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BRIEF COMMUNICATION
Cellular and Molecular Biology
Intratumor heterogeneity of PD-L1 expression in head and
neck squamous cell carcinoma
Jacob H. Rasmussen1, Giedrius Lelkaitis2, Katrin Håkansson3, Ivan R. Vogelius3, Helle H. Johannesen4, Barbara M. Fischer4,5,
Søren M. Bentzen6, Lena Specht3, Claus A. Kristensen3, Christian von Buchwald1, Irene Wessel1 and Jeppe Friborg3
Intratumor heterogeneity may contribute to the ambiguous clinical results on PD-L1 status as a predictor for immunotherapy
response in patients with HNSCC. This decreases the utility of PD-L1 expression from single tumour biopsies as a predictive
biomarker. In this prospective study, intratumor heterogeneity of PD-L1 expression in HNSCC was investigated with both Tumour
Proportion Score (TPS) and Combined Positive Score (CPS). Thirty-three whole surgical specimens from 28 patients with HNSCC
were included. PD-L1 expression in six random core biopsies from each surgical specimen was used to assess the concordance
between multiple biopsies and the negative predictive value of a single negative core biopsy. With 1% cut off, 36% of the
specimens were concordant with TPS and 52% with CPS. With a 50% cut-off value the concordance was 70% with TPS and 55%
with CPS. Defining a tumour as positive if just a single-one of the biopsies was positive, the negative predictive value (NPV) of a
single negative core biopsy was 38.9 and 0% (1% cut off), and 79.9% and 62.8% (50% cut off) for TPS and CPS, respectively. In
conclusion, PD-L1 positivity varies markedly within the tumour, both with TPS and CPS, challenging the utility of this biomarker.
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BACKGROUND
Head and neck squamous cell carcinoma (HNSCC) is a biologically
and clinically heterogenous disease.1 Primary treatment includes
surgery and/or radiotherapy, with or without concomitant
chemotherapy, but ~15–50% of the patients experience treatment
failure,2 HPV association being the most important prognostic
factor. Patients with recurrent or metastatic disease have a very
poor prognosis and systemic treatment with the combination
of cetuximab, platinum and fluorouracil is standard first line
treatment.3 Recently, immune checkpoint inhibitors, i.e. antibodies
targeting the programmed cell death protein-1 (PD-1)/
programmed death ligand 1 (PD-L1) signalling pathway have
been approved by the FDA for second-line treatment of
HNSCC.4 Nivolumab, a PD-1 inhibitor, demonstrated improved
response rate and overall survival compared to conventional
chemotherapy5,6 in a randomised phase III trial. Pembrolizumab,
another PD-1 inhibitor, yielded response rates comparable to
nivolumab in phase I, II and III studies.7,8 These treatments are
costly, have side effects,9,10 and not all patients respond to
treatment. This emphasises the need for predictive biomarkers
and there is evidence suggesting a better response to treatment
in patients whose tumours express PD-L1.6,11 However, clinical
response has also occurred in patients with PD-L1 negative
tumours and, conversely, PD-L1 expressing tumours have not
responded to treatment. FDA has approved nivolumab and
pembrolizumab for use in head and neck cancer patients with
disease progression on or after platinum-based therapy, and
nivolumab has been approved by EMA for use in Europe under
a similar indication. Pembrolizumab, however, is approved only
for adults whose tumours express PD-L1 with a ≥50% Tumour
Proportion Score (TPS) and progressing on or after platinum-
containing chemotherapy. Also, a Combined Positive Score (CPS)
for PD-L1 expression has been shown to be predictive of benefit in
recent studies in HNSCC.7 In other tumour types (e.g. non-small
cell lung cancer and urothelial carcinoma), immunotherapy is
approved only for patients with PD-L1 positive tumours. However,
the cut-off value for PD-L1 expression is controversial, as
demonstrated in a recent study in non-small cell lung cancer.12
Intratumor heterogeneity may be part of the explanation for this
controversy and could invalidate the use of PD-L1 expression as a
predictive marker for treatment selection. Thus, intratumor
heterogeneity may have a direct impact on patient treatment
not only for patients with HNSCC.
There are at least three main reasons for variability in PD-L1
expression between studies, between patients, and within
tumours. First, technical reasons: different protocols for immuno-
histochemical staining use different antibodies with varying
binding affinities, different scoring systems and criteria for
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positivity.13,14 Second, clinical reasons: scoring will depend on
biopsy quality and inherently be subject to interobserver
variability.15,16 Thirdly, biological reasons: PD-L1 expression varies
within a given tumour.17,18 Expression of PD-L1 is usually assessed
from single tumour biopsies, which will be affected by intratumor
heterogeneity. To our knowledge, no study has investigated
the intratumor heterogeneity in PD-L1 expression in head and
neck cancer.
METHODS
Patients and specimens
In this prospective study, patients with HNSCC referred for curative
surgery were enroled. Only patients with tumour diameters >1.5 cm
were included. No patient received immunotherapy. The study was
approved by the Regional Committee on Health Research Ethics,
approval number H-16049387 and the study was performed in
accordance with the Declaration of Helsinki.
Histology and immunohistochemistry
Figure 1 illustrates the workflow in the histologic processing. All
tumours were removed en bloc and after surgery all specimens
were formalin fixated, embedded in paraffin and sectioned in 2–3
mm consecutive tissue blocks (Fig. 1a, b). Six tissue blocks from
each specimen were selected randomly and core biopsied in an
area with representative tumour tissue assessed from a 4-µm
section stained with haematoxylin and eosin (H&E) (Fig. 1c, d). A 3
mm wide core biopsy was taken from each of the selected tumour
blocks and used to construct tissue micro array (TMA) blocks
(Fig. 1e). 4-µm sections were made from the TMA blocks and
stained for H&E and p40 (platform Dako Omnis, clone BC28, code
ACI3066C, mouse monoclonal anti-human, 1+ 50, Biocare Med-
ical, Pacheco CA, USA) to assess biopsy quality as percentage
tumour in the core biopsy and percentage of vital squamous
tumour cells in the biopsy. PD-L1 expression was assessed as TPS
and as CPS using platform Autostainer Link 48, clone 28-8,
pharmDx kit, rabbit monoclonal anti-human, 1+ 200, Dako
(Fig. 1f–g). Discordance or concordance in dichotomised PD-L1
positivity was estimated using 1% and 50% as cut-off values with
both TPS and CPS.
RESULTS
Patients and specimens
Overall twenty eight patients were included, sixteen males
and twelve females. Sixteen patients had a tumour in the oral
cavity, four in the oropharynx (one p16 positive), three in the
hypopharynx, two in the maxillary sinus, and three had only tumours
in a lymph node. Five patients had both a primary lesion and a
lymph node metastasis yielding a total of 33 lesions. Two of the
specimens only had four tumour blocks and another two only had
five tumour blocks yielding 192 tumour blocks for TMA construction.
PD-L1 expression
Figure 2a, b depicts the full PD-L1 score from each core biopsy with
TPS and CPS, respectively. Using a 1% cut-off value to define
positivity, 36% of the specimens were concordant (all positive or all
negative) in the six biopsies from each lesion with TPS and 52%
were concordant with CPS. With a 50% cut off, the concordance
was higher at 70% with TPS and 54% with CPS. For each score and
each threshold of positivity, we define the ground truth as the
tumour being PD-L1 positive if any of the cores from the tumour
specimen is positive. With this definition, the positive predictive
value of a single biopsy is identical 100% regardless of whether TPS
or CPS is used to score PD-L1 expression. The negative predictive
value (NPV) of a single negative biopsy is 38.9% with TPS. The NPV
of a single negative biopsy with CPS using 1% cut-off value was 0%
(Fig. 2) as none of the 33 lesions studied here were negative for
PD-L1 expression in all six core biopsies with this definition. With
50% cut-off value, the NPV= 79.9% with TPS and 62.8% with CPS
(Fig. 2). The scatter plots in Fig. 2a, b illustrates that any clinical/
biological cut-off value for positivity would still be subject to
intratumor heterogeneity if assessed from a single biopsy.
Performing double biopsies could increase the predictive value;
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Fig. 1 a–g illustrates the workflow and histologic processing in the study. a shows how the lesions were sectioned contiguously into tumour
blocks, yielding 11 tumour blocks in this particularly case. Each red line on (a) corresponds to the specific tumour block number in Fig. 2b. Six
blocks were selected randomly for further histologic processing. c and d depicts the 4-µm section stained with haematoxylin and eosin from
block 2 and block 8. The black circle indicates from where the 3mm core biopsy was performed. e illustrates a sectioned from a tissue micro
array block stained for PD-L1 expression. f and g are the two cores marked with the red square in 1E and correspond the two cores in shown
in c, d
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the NPV with double biopsies was 56.8% and 86.8% with TPS and
0% and 73.8% for CPS with 1% and 50% cut-offs, respectively
(Fig. 2), again calling the tumour negative if and only if both
biopsies were negative on the assay. There was no significant
correlation between concordance in PD-L1 expression and tumour
volume on magnetic resonance imaging. Heterogeneity in PD-L1
expression was observed both in small and in large tumours (data
not shown). In the five patients with both a primary lesion and a
lymph node lesion, there were no significant differences in PD-L1
expression between the primary lesions and the lymph nodes. The
actual values for the respective lesions are shown in Fig. 2a, b.
DISCUSSION
In this study, all biopsies were performed as 3 mm core biopsies
from whole specimen tumour blocs (Fig. 1). The core biopsies
were selected from areas with representative tumour tissue as
verified by the pathologist. Clinical biopsies used to assess PD-L1
expression for first- or second-line treatment may very well
contain less tumour tissue, which will increase the uncertainty
further. One desired property for a predictive biomarker is a high
NPV and although the NPV using a 50% cut off for positivity with
TPS was better at 79.9%, the majority of lesions (64%) was
classified as negative using this definition (Fig. 2a). Although CPS
in some studies has shown to be predictive for response in
patients with recurrent HNSCC, no lesions were true negative with
a cut-off value at 1%. This study illustrates the challenges of using
PD-L1 as a predictive biomarker. While reporting the actual TPS or
CPS value may convey biological information, using this biomarker
for clinical decision making still requires a binary classification into
positive or negative lesions.
In conclusion, both with TPS and CPS the assessed PD-L1
positivity varies markedly within the tumour in this patient series
(Fig. 2), which limits the utility of this biomarker. However,
identifying the optimal cut point for discrimination between
responders and non-responders to a specific agent is a clinical/
biological problem.
Intratumor heterogeneity most likely contributes to the
ambiguous results on PD-L1 status seen in the Checkmate6 and
Keynote8 studies of HNSCC patients and challenges the use of PD-
L1 expression from single tumour biopsies as a predictor for
immunotherapy in HNSCC patients. In future trials, the use of
repeated biopsies or multiple tumour sampling from head and
neck tumours as well as reporting the actual value of PD-L1
expression could be considered for better prediction of tumour
response to immune checkpoint inhibitors targeting the PD-1/PD-
L1 signalling pathway.
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Fig. 2 a shows a scatter plot of the PD-L1 score in each biopsy with tumour proportion score (TPS) and b shows the PD-L1 expression with
combined positive score (CPS). In a and b the y-axis depicts the PD-L1 score from 0–100%. The x-axis depicts the 33 lesions ranked by mean
PD-L1 score marked with a black circle for TPS and CPS, respectively. The crosses depict the actual score from each of the six biopsies. As an
example, in lesion 1 and 2 all biopsies scored 0% in a. The black dashed lines marks 1% cut off and 50% cut-off values. The insert in the upper
left corner of both (a) and (b) depicts the negative predictive value of a single negative core biopsy using a 1% cut off and 50% cut off for
positivity with TPS (2A) and CPS (2B) in case of one biopsy and with double biopsy. The ground truth is assumed to be that a tumour is
positive if any of the six core biopsies are positive. For the five patients with two lesions, lesion 30, 15, 25, 7 and 2 is the primary lesions and
lesion 32, 12, 26, 8 and 1 is the corresponding lymph node lesions in a. Lesion 29, 17, 23, 2 and 12 is the primary lesions in b and lesion 32, 15,
24, 5 and 13 the corresponding lymph node lesions
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